Cargando…

Morbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs

BACKGROUND: While up to 45% of individuals with intellectual and developmental disabilities (IDD) have a comorbid psychiatric disorder, and antipsychotics are commonly prescribed, gender differences in the safety of antipsychotics have rarely been studied in this population. AIMS: To compare men and...

Descripción completa

Detalles Bibliográficos
Autores principales: Vigod, Simone N., Lunsky, Yona, Cobigo, Virginie, Wilton, Andrew S., Somerton, Sarah, Seitz, Dallas P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal College of Psychiatrists 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998937/
https://www.ncbi.nlm.nih.gov/pubmed/27703773
http://dx.doi.org/10.1192/bjpo.bp.116.002691
_version_ 1782450039051780096
author Vigod, Simone N.
Lunsky, Yona
Cobigo, Virginie
Wilton, Andrew S.
Somerton, Sarah
Seitz, Dallas P.
author_facet Vigod, Simone N.
Lunsky, Yona
Cobigo, Virginie
Wilton, Andrew S.
Somerton, Sarah
Seitz, Dallas P.
author_sort Vigod, Simone N.
collection PubMed
description BACKGROUND: While up to 45% of individuals with intellectual and developmental disabilities (IDD) have a comorbid psychiatric disorder, and antipsychotics are commonly prescribed, gender differences in the safety of antipsychotics have rarely been studied in this population. AIMS: To compare men and women with IDD on medical outcomes after antipsychotic initiation. METHOD: Our population-based study in Ontario, Canada, compared 1457 women and 1951 men with IDD newly initiating antipsychotic medication on risk for diabetes mellitus, hypertension, venous thromboembolism, myocardial infarction, stroke and death, with up to 4 years of follow-up. RESULTS: Women were older and more medically complex at baseline. Women had higher risks for venous thromboembolism (HR 1.72, 95% CI 1.15–2.59) and death (HR 1.46, 95% CI 1.02–2.10) in crude analyses; but only thromboembolism risk was greater for women after covariate adjustment (aHR 1.58, 95% CI 1.05–2.38). CONCLUSIONS: Gender should be considered in decision-making around antipsychotic medications for individuals with IDD. DECLARATION OF INTEREST: None. COPYRIGHT AND USAGE: © The Royal College of Psychiatrists 2016. This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) licence.
format Online
Article
Text
id pubmed-4998937
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher The Royal College of Psychiatrists
record_format MEDLINE/PubMed
spelling pubmed-49989372016-10-04 Morbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs Vigod, Simone N. Lunsky, Yona Cobigo, Virginie Wilton, Andrew S. Somerton, Sarah Seitz, Dallas P. BJPsych Open Paper BACKGROUND: While up to 45% of individuals with intellectual and developmental disabilities (IDD) have a comorbid psychiatric disorder, and antipsychotics are commonly prescribed, gender differences in the safety of antipsychotics have rarely been studied in this population. AIMS: To compare men and women with IDD on medical outcomes after antipsychotic initiation. METHOD: Our population-based study in Ontario, Canada, compared 1457 women and 1951 men with IDD newly initiating antipsychotic medication on risk for diabetes mellitus, hypertension, venous thromboembolism, myocardial infarction, stroke and death, with up to 4 years of follow-up. RESULTS: Women were older and more medically complex at baseline. Women had higher risks for venous thromboembolism (HR 1.72, 95% CI 1.15–2.59) and death (HR 1.46, 95% CI 1.02–2.10) in crude analyses; but only thromboembolism risk was greater for women after covariate adjustment (aHR 1.58, 95% CI 1.05–2.38). CONCLUSIONS: Gender should be considered in decision-making around antipsychotic medications for individuals with IDD. DECLARATION OF INTEREST: None. COPYRIGHT AND USAGE: © The Royal College of Psychiatrists 2016. This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) licence. The Royal College of Psychiatrists 2016-04-20 /pmc/articles/PMC4998937/ /pubmed/27703773 http://dx.doi.org/10.1192/bjpo.bp.116.002691 Text en © 2016 The Royal College of Psychiatrists http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) licence (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Paper
Vigod, Simone N.
Lunsky, Yona
Cobigo, Virginie
Wilton, Andrew S.
Somerton, Sarah
Seitz, Dallas P.
Morbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs
title Morbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs
title_full Morbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs
title_fullStr Morbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs
title_full_unstemmed Morbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs
title_short Morbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs
title_sort morbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs
topic Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998937/
https://www.ncbi.nlm.nih.gov/pubmed/27703773
http://dx.doi.org/10.1192/bjpo.bp.116.002691
work_keys_str_mv AT vigodsimonen morbidityandmortalityofwomenandmenwithintellectualanddevelopmentaldisabilitiesnewlyinitiatingantipsychoticdrugs
AT lunskyyona morbidityandmortalityofwomenandmenwithintellectualanddevelopmentaldisabilitiesnewlyinitiatingantipsychoticdrugs
AT cobigovirginie morbidityandmortalityofwomenandmenwithintellectualanddevelopmentaldisabilitiesnewlyinitiatingantipsychoticdrugs
AT wiltonandrews morbidityandmortalityofwomenandmenwithintellectualanddevelopmentaldisabilitiesnewlyinitiatingantipsychoticdrugs
AT somertonsarah morbidityandmortalityofwomenandmenwithintellectualanddevelopmentaldisabilitiesnewlyinitiatingantipsychoticdrugs
AT seitzdallasp morbidityandmortalityofwomenandmenwithintellectualanddevelopmentaldisabilitiesnewlyinitiatingantipsychoticdrugs